| 1 |
Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
|
| 2 |
Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev 2021;100:102288. [PMID: 34525422 DOI: 10.1016/j.ctrv.2021.102288] [Reference Citation Analysis]
|
| 3 |
Faghfuri E, Shadbad MA, Faghfouri AH, Soozangar N. Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. Immunotherapy 2022. [PMID: 35232264 DOI: 10.2217/imt-2021-0285] [Reference Citation Analysis]
|
| 4 |
Bao T, Wang Z, Xu J. Immune-Related lncRNAs Pairs to Construct a Novel Signature for Predicting Prognosis in Gastric Cancer. Front Surg 2022;9:807778. [DOI: 10.3389/fsurg.2022.807778] [Reference Citation Analysis]
|
| 5 |
Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Reference Citation Analysis]
|
| 6 |
Kyuno D, Takasawa A, Takasawa K, Ono Y, Aoyama T, Magara K, Nakamori Y, Takemasa I, Osanai M. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 2021;:1967080. [PMID: 34486479 DOI: 10.1080/21688370.2021.1967080] [Reference Citation Analysis]
|
| 7 |
Fernandez-Rozadilla C, Simões AR, Lleonart ME, Carnero A, Carracedo Á. Tumor Profiling at the Service of Cancer Therapy. Front Oncol 2020;10:595613. [PMID: 33505911 DOI: 10.3389/fonc.2020.595613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Chen Y, Zhou Q, Wang H, Zhuo W, Ding Y, Lu J, Wu G, Xu N, Teng L. Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers (Basel) 2020;12:E2236. [PMID: 32785164 DOI: 10.3390/cancers12082236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 9 |
Yu J, Liu H, Zeng X, Zhao Y, Jiang D, Lu H, Qian J. Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer: A meta-analysis. PLoS One 2021;16:e0250295. [PMID: 33901218 DOI: 10.1371/journal.pone.0250295] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Oh S, Yang H, Oh HR, Seo M, Lee C, Kim Y, Choi JY, Kim NY, Cheon GJ, Kang KW, Shin YK, Youn H. Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.04.003] [Reference Citation Analysis]
|
| 11 |
Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188615. [PMID: 34403771 DOI: 10.1016/j.bbcan.2021.188615] [Reference Citation Analysis]
|
| 12 |
Qian S, Villarejo-Campos P, García-Olmo D. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. J Clin Med 2021;10:5050. [PMID: 34768570 DOI: 10.3390/jcm10215050] [Reference Citation Analysis]
|
| 13 |
Kole C, Charalampakis N, Tsakatikas S, Kouris NI, Papaxoinis G, Karamouzis MV, Koumarianou A, Schizas D. Immunotherapy for gastric cancer: a 2021 update. Immunotherapy 2021. [PMID: 34784774 DOI: 10.2217/imt-2021-0103] [Reference Citation Analysis]
|
